Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2384 - Clinical outcomes of delayed start of trastuzumab treatment in patients with early breast cancer: ml25232 study


11 Sep 2017


Poster display session


Cytotoxic Therapy;  Breast Cancer


Semir Beslija


Annals of Oncology (2017) 28 (suppl_5): v43-v67. 10.1093/annonc/mdx362


S. Beslija1, T. Ceric1, B. Hasanbegovic1, A. Kurtovic-Kozaric2, A. Pasic1, N. Mahic1, M. Kalamujic1, A. Cardzic1, J. Alidzanovic3, I. Marjanovic4, A. Mekic-Abazovic5

Author affiliations

  • 1 Oncology, Clinical Center, University of Sarajevo, 71000 - Sarajevo/BA
  • 2 Pathology, Cytology And Human Genetics, Clinical Centre of Sarajevo University, 71000 - Sarajevo/BA
  • 3 Oncology, University Clincal Center Tuzla, 75000 - Tuzla/BA
  • 4 Oncology, University Clinical Hospital Mostar, 88000 - Mostar/BA
  • 5 Oncoogy, Hematology And Radiation Unit, Cantonal Hospital Zenica, 72000 - Zenica/BA


Abstract 2384


Breast cancer patients in low and middle income countries have limited access to targeted therapies such as trastuzumab. The discontinuous availability of trastuzumab created waiting lists and subsequent very delayed treatment. Since few studies have systematically analyzed possible deleterious effect of delayed trastuzumab treatment, we designed a study to investigate its consequences on overall survival and disease-free survival.


This was a multicenter cohort study of HER2-positive early breast cancer patients (n = 223) diagnosed between 01/05/2005 and 01/05/2010 in the Federation of Bosnia and Herzegovina. The study began in 01/01/2010, and enrollment was completed in 30/06/2012. Last follow up and cut off date for analysis was 31/03/2015.


A total of 223 women (median 55 years; IQR: 49-61 years) were recruited. Since 131 (59%) patients waited for > 6 months after surgery to receive trastuzumab, we categorized our patient cohort into three groups: non-waiting group (n = 92; wait time < 6 months), and waiting group 1 (n = 85; wait time between 7 to 12 months) and waiting group 2 (n = 46; > 13 month wait). OS at 5 years in non-waiting group was 84%, compared to 72% in wait group 1 and 75% in wait group 2 (p > 0.05). DFS at 5 years in the non-wait group was 79%, compared to 65% in wait group 1, and 68% in wait group 2 (p > 0.05).


Unfortunate and unique circumstances in developing countries have created waiting lists for trastuzumab treatment—our systematic analysis of 223 women has shown that delayed start of trastuzumab treatment does not have a statistically significant effect on clinical outcomes, but shows a trend towards worse OS and DFS for women with delayed treatment. Thus, trastuzumab treatment has a persistent benefit even when administered with delayed start.

Clinical trial identification


Legal entity responsible for the study





T. Ceric: Honoraria: Roche, Novartis, Pfizer. Consulting or Advisory Role: Roche, Novartis, Pfizer. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.